U-turn on the treatment of prostate cancer with abiraterone
Posted May 16 2012 3:48am
As totalhealth wrote in February 2012 , the National Institute for Health and Clinical Excellence (NICE) rejected the drug abiraterone for the treatment of prostate cancer. This was due to its limited benefit but high cost. However, new draft guidance published today by NICE, recommends that abiraterone should be used as a treatment option for castration-resistantA microbe, such as a type of bacteria, that is able to resist the effects of antibiotics or other drugs. metastatic prostate cancer.
This U-turn is the result of discussions between NICE and one of the manufacturers of the drug who was able to revise its patient access scheme and provide the drug to the NHS at a discounted price.
Sir Andrew Dillon, Chief Executive of NICE said that the regulatory body is “…very pleased… [abiraterone] is an effective treatment, potentially extending life by more than three months, and it also allows patients to be treated at home as it can be taken orally.”
NHS bodies will now be able to make decisions locally about the availability and prescription of the treatment although, once the final approval is published, it is likely to be offered to patients who have previously been treated with a docetaxel-containing chemotherapyThe use of chemical substances to treat disease, particularly cancer. regimen and are resistant to castration due to the progression of metastasesSecondary tumours’ that result from the spread of a malignant tumour to other parts of the body. or a rise in prostate-specific antigenAn enzyme that is produced by the prostate, a gland that surrounds the urethra near the bladder. High levels are present in the blood when the prostate gland is enlarged or inflamed. (PSAAn abbreviation for prostate-specific antigen, an enzyme that is produced by the prostate. High levels are present in the blood when the prostate gland is enlarged or inflamed.) levels.
For further information about new developments in the treatment of advanced prostate cancer, please click here or to arrange a consultation with totalhealth’s specialist in advanced prostate cancer, Professor Agamemnon Epenetos , please click here .